Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants

Liming Lu, Leiyu Shi, Jingchun Zeng, Zehuai Wen

Research output: Contribution to journalArticle

Abstract

Background: Previous meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results. In addition, the threshold effect of different doses, frequencies and durations of aspirin use in preventing breast cancer have yet to be established. Results: The search yielded 13 prospective cohort studies (N=857,831 participants) that reported an average of 7.6 cases/1,000 person-years of breast cancer during a follow-up period of from 4.4 to 14 years. With a random effects model, a borderline significant inverse association was observed between overall aspirin use and breast cancer risk, with a summarized RR = 0.94 (P = 0.051, 95% CI 0.87-1.01). The linear regression model was a better fit for the dose-response relationship, which displayed a potential relationship between the frequency of aspirin use and breast cancer risk (RR = 0.97, 0.95 and 0.90 for 5, 10 and 20 times/week aspirin use, respectively). It was also a better fit for the duration of aspirin use and breast cancer risk (RR = 0.86, 0.73 and 0.54 for 5, 10 and 20 years of aspirin use). Methods: We searched MEDLINE, EMBASE and CENTRAL databases through early October 2016 for relevant prospective cohort studies of aspirin use and breast cancer risk. Meta-analysis of relative risks (RR) estimates associated with aspirin intake were presented by fixed or random effects models. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Conclusion: Our study confirmed a dose-response relationship between aspirin use and breast cancer risk. For clinical prevention, long term (> 5 years) consistent use (2-7 times/week) of aspirin appears to be more effective in achieving a protective effect against breast cancer.

Original languageEnglish (US)
Pages (from-to)40389-40401
Number of pages13
JournalOncotarget
Volume8
Issue number25
DOIs
StatePublished - 2017

Fingerprint

Chemoprevention
Aspirin
Meta-Analysis
Cohort Studies
Breast Neoplasms
Linear Models
Prospective Studies
MEDLINE
Databases

Keywords

  • Aspirin
  • Breast cancer
  • Dose-response Meta-analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Aspirin as a potential modality for the chemoprevention of breast cancer : A dose-response meta-analysis of cohort studies from 857,831 participants. / Lu, Liming; Shi, Leiyu; Zeng, Jingchun; Wen, Zehuai.

In: Oncotarget, Vol. 8, No. 25, 2017, p. 40389-40401.

Research output: Contribution to journalArticle

@article{b8a09dbf8692467389133de7ce944d53,
title = "Aspirin as a potential modality for the chemoprevention of breast cancer: A dose-response meta-analysis of cohort studies from 857,831 participants",
abstract = "Background: Previous meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results. In addition, the threshold effect of different doses, frequencies and durations of aspirin use in preventing breast cancer have yet to be established. Results: The search yielded 13 prospective cohort studies (N=857,831 participants) that reported an average of 7.6 cases/1,000 person-years of breast cancer during a follow-up period of from 4.4 to 14 years. With a random effects model, a borderline significant inverse association was observed between overall aspirin use and breast cancer risk, with a summarized RR = 0.94 (P = 0.051, 95{\%} CI 0.87-1.01). The linear regression model was a better fit for the dose-response relationship, which displayed a potential relationship between the frequency of aspirin use and breast cancer risk (RR = 0.97, 0.95 and 0.90 for 5, 10 and 20 times/week aspirin use, respectively). It was also a better fit for the duration of aspirin use and breast cancer risk (RR = 0.86, 0.73 and 0.54 for 5, 10 and 20 years of aspirin use). Methods: We searched MEDLINE, EMBASE and CENTRAL databases through early October 2016 for relevant prospective cohort studies of aspirin use and breast cancer risk. Meta-analysis of relative risks (RR) estimates associated with aspirin intake were presented by fixed or random effects models. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Conclusion: Our study confirmed a dose-response relationship between aspirin use and breast cancer risk. For clinical prevention, long term (> 5 years) consistent use (2-7 times/week) of aspirin appears to be more effective in achieving a protective effect against breast cancer.",
keywords = "Aspirin, Breast cancer, Dose-response Meta-analysis",
author = "Liming Lu and Leiyu Shi and Jingchun Zeng and Zehuai Wen",
year = "2017",
doi = "10.18632/oncotarget.16315",
language = "English (US)",
volume = "8",
pages = "40389--40401",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Aspirin as a potential modality for the chemoprevention of breast cancer

T2 - A dose-response meta-analysis of cohort studies from 857,831 participants

AU - Lu, Liming

AU - Shi, Leiyu

AU - Zeng, Jingchun

AU - Wen, Zehuai

PY - 2017

Y1 - 2017

N2 - Background: Previous meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results. In addition, the threshold effect of different doses, frequencies and durations of aspirin use in preventing breast cancer have yet to be established. Results: The search yielded 13 prospective cohort studies (N=857,831 participants) that reported an average of 7.6 cases/1,000 person-years of breast cancer during a follow-up period of from 4.4 to 14 years. With a random effects model, a borderline significant inverse association was observed between overall aspirin use and breast cancer risk, with a summarized RR = 0.94 (P = 0.051, 95% CI 0.87-1.01). The linear regression model was a better fit for the dose-response relationship, which displayed a potential relationship between the frequency of aspirin use and breast cancer risk (RR = 0.97, 0.95 and 0.90 for 5, 10 and 20 times/week aspirin use, respectively). It was also a better fit for the duration of aspirin use and breast cancer risk (RR = 0.86, 0.73 and 0.54 for 5, 10 and 20 years of aspirin use). Methods: We searched MEDLINE, EMBASE and CENTRAL databases through early October 2016 for relevant prospective cohort studies of aspirin use and breast cancer risk. Meta-analysis of relative risks (RR) estimates associated with aspirin intake were presented by fixed or random effects models. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Conclusion: Our study confirmed a dose-response relationship between aspirin use and breast cancer risk. For clinical prevention, long term (> 5 years) consistent use (2-7 times/week) of aspirin appears to be more effective in achieving a protective effect against breast cancer.

AB - Background: Previous meta-analyses on the relationship between aspirin use and breast cancer risk have drawn inconsistent results. In addition, the threshold effect of different doses, frequencies and durations of aspirin use in preventing breast cancer have yet to be established. Results: The search yielded 13 prospective cohort studies (N=857,831 participants) that reported an average of 7.6 cases/1,000 person-years of breast cancer during a follow-up period of from 4.4 to 14 years. With a random effects model, a borderline significant inverse association was observed between overall aspirin use and breast cancer risk, with a summarized RR = 0.94 (P = 0.051, 95% CI 0.87-1.01). The linear regression model was a better fit for the dose-response relationship, which displayed a potential relationship between the frequency of aspirin use and breast cancer risk (RR = 0.97, 0.95 and 0.90 for 5, 10 and 20 times/week aspirin use, respectively). It was also a better fit for the duration of aspirin use and breast cancer risk (RR = 0.86, 0.73 and 0.54 for 5, 10 and 20 years of aspirin use). Methods: We searched MEDLINE, EMBASE and CENTRAL databases through early October 2016 for relevant prospective cohort studies of aspirin use and breast cancer risk. Meta-analysis of relative risks (RR) estimates associated with aspirin intake were presented by fixed or random effects models. The dose-response meta-analysis was performed by linear trend regression and restricted cubic spline regression. Conclusion: Our study confirmed a dose-response relationship between aspirin use and breast cancer risk. For clinical prevention, long term (> 5 years) consistent use (2-7 times/week) of aspirin appears to be more effective in achieving a protective effect against breast cancer.

KW - Aspirin

KW - Breast cancer

KW - Dose-response Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85020963239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020963239&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16315

DO - 10.18632/oncotarget.16315

M3 - Article

C2 - 28418881

AN - SCOPUS:85020963239

VL - 8

SP - 40389

EP - 40401

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -